Clinical Trials Directory

Trials / Terminated

TerminatedNCT03334734

Phase 2a Study of PBTZ169

Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Nearmedic Plus LLC · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Multicenter, open, randomized study with active control (isoniazid) to evaluate the early antibacterial activity, safety and pharmacokinetics of the drug PBTZ169 (capsules 80 mg) when used in patients with first-diagnosed tuberculosis of the respiratory system with bacterial excretion and saved bacterial susceptibility to isoniazid and rifampicin

Detailed description

This phase 2a study is aimed to evaluate the early bactericidal activity of a new anti-tuberculosis drug PBTZ169 (capsules 80 mg), and its results will allow preliminary evaluate antimycobacterial properties of PBTZ169 and confirm a potentially more effective dose for subsequent studies. This study is an open, randomized comparative efficacy (on the parameter of early bactericidal activity), safety and pharmacokinetics study of PBTZ169 in patients with first-diagnosed lung tuberculosis and preserved sensitivity to base antimycobacterial drugs: rifampicin and isoniazid. Within the framework of the study, it is planned to use the studied drugs (PBTZ169 and isoniazid) as monotherapy within 14 days. Isoniazid is used as a "positive control", that is, in order to determine whether the method of assessing efficacy on the parameter of early bactericidal activity is working.

Conditions

Interventions

TypeNameDescription
DRUGPBTZ169Once a day for 14 days
DRUGIsoniazidOnce a day for 14 days

Timeline

Start date
2016-12-16
Primary completion
2017-09-10
Completion
2018-02-22
First posted
2017-11-07
Last updated
2020-03-09
Results posted
2020-03-09

Source: ClinicalTrials.gov record NCT03334734. Inclusion in this directory is not an endorsement.